Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00564395 · ClinicalTrials.gov registry record · Phase 4
Detemir: Role in Type 1 Diabetes
A Phase 4 study of Type 1 Diabetes Mellitus, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00564395: Completed Phase 4 study of Type 1 Diabetes Mellitus, sponsored by Montefiore Medical Center.
NCT00564395 is a Phase 4 study of Type 1 Diabetes Mellitus that has completed, run by Montefiore Medical Center. The registered enrollment target is 18 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00564395, a Phase 4 study of Type 1 Diabetes Mellitus, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart). It is hypothesized that there is no difference in the patterns of blood sugars when detemir is given in the same syringe or in separate syringes with rapid acting insulin.
Primary Outcome
Blood glucose concentration in terms of mean AUC (0-48 hours)was determined in subjects treated with either Insulin Detemir mixed with RAI or Insulin Detemir and RAI as separate subcutaneous injections.
Conditions Studied
Interventions
- DRUG Insulin Detemir mixed with RAI injection
- DRUG Insulin Detemir and RAI injection
Study Locations (1)
Texas
- Texas Children's Hospital Endocrine and Diabetes Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
What the finished NCT00564395 record still lists
NCT00564395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Insulin Detemir mixed with RAI injection is the first listed.
NCT00564395 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00564395 about?
NCT00564395 is a clinical study titled "Detemir: Role in Type 1 Diabetes". Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart). It is hypothesized that there is no difference in the patterns of blood sugars when detemir is given in the same syringe or in separate syringes with rapid a...
What is the current status of trial NCT00564395?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2007-08. Estimated completion is 2010-05.
What conditions does trial NCT00564395 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT00564395?
The interventions under investigation include: Insulin Detemir mixed with RAI injection (DRUG), Insulin Detemir and RAI injection (DRUG).
Who is sponsoring clinical trial NCT00564395?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00564395 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00564395's enrollment target sits among peer trials
18 94th of 112 higher than 18 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
COMPLETED · Phase 4
-
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
COMPLETED · Phase 4
-
The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
COMPLETED · Phase 4
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
- NCT03326310 · 18 participants · Phase 1
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia